Risk factors for rifampin-monoresistant tuberculosis: A case-control study

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 2, 1999, Pages 468-472

  Sandman, Laurie ^a   Schluger, Neil W ^a,b   Davidow, Amy L ^a   Bonk, Stanley ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia Univ Coll of Phys/Surg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALABSORPTION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0033046295     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.2.9805097     Document Type: Article

References (20)

1. Schluger, N., T. Harkin, and W. Rom. 1996. Principles of therapy of tuberculosis. In W. N. Rom and S. Garay, editors. Tuberculosis. Little Brown, Boston.
2. Moore, M., I. M. Onorato, E. McCray, and K. G. Castro. 1997. Trends in drug-resistant tuberculosis in the United States, 1993-1996. J.A.M.A. 278:833-837.
3. Small, P. M., R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, and G. K. Schoolnik. 1993. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328:1137-1144.
4. Perlman, D. C., and N. Salomon. 1996. Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis (letter). Am. J. Respir. Crit. Care Med. 154:1213.
5. Mitchison, D. A. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15.
6. Mahmoudi, A., and M. D. Iseman. 1993. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. J.A.M.A. 270:65-68.
7. March, F., X. Garriga, P. Rodriguez, C. Moreno, M. Garrigo, P. Coll, and G. Prats. 1997. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin. Infect. Dis. 25:1044-1047.
8. Frieden, T. R., T. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
9. Bishai, W. R., N. M. H. Graham, S. Harrington, C. Page, K. Moore-Rice, N. Hooper, and R. E. Chaisson. 1996. Rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N. Engl. J. Med. 334:1573-1576.
10. Lutfey, M., P. Della-Latta, V. Kapur, L. A. Palumbo, D. Gurner, G. Stotzky, K. Brudney, J. Dobkin, A. Moss, J. M. Musser, and B. N. Kreiswirth. 1996. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 153:837-840.
11. Nolan, C. M., D. L. Williams, M. D. Cave, K. D. Eisenach, H. el-Hajj, T. M. Hooton, R. L. Thompson, and S. V. Goldberg. 1995. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am. J. Respir. Crit. Care Med. 152:1067-1071.
12. Munsiff, S. S., S. Joseph, A. Ebrahimzadeh, and T. R. Frieden. 1997. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin. Infect. Dis. 25:1465-1467.
13. Hong Kong Chest Service/British Medical Research Council. 1975. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 56:81-96.
14. Park, M. M., A. L. Davis, N. W. Schluger, H. Cohen, and W. N. Rom. 1996. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am. J. Respir. Crit. Care Med. 153:317-324.
15. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550
16. Peloquin, C. A., A. T. Nitta, W. J. Burman, K. F. Brudney, J. R. Miranda-Massari, M. E. McGuinness, S. E. Berning, and G. T. Gerena. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-925.
17. Center for Disease Control. 1996. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. Morbid. Mortal. Wkly. Rep. 45:921-925.
18. Vernon, A., A. Khan, L. Bozeman, and Y. Wang. 1998. Update on U.S. Public Health Service (USPHS) study 22: a trial of once weekly isoniazid and rifapentine in the continuation phase of TB treatment (abstract). Am. J. Respir. Crit. Care Med. 157:A467.
19. Lipstich, M., and B. R. Levin. 1998. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 2:187-199.
20. Ridzon, R., C. G. Whitney, M. T. McKenna, J. P. Taylor, S. H. Ashkar, A. T. Nitta, S. M. Harvey, S. Valway, C. Woodley, R. Cooksey, and I. M. Onorato. 1998. Risk factors for rifampin mono-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 157:1881-1884.